IFNB1 and COVID-19: A number of clinical studies have shown that the IFN-β 1b combination has potential value in clinical improvement time, nucleic acid negative conversion time and mortality of COVID-19 patients compared to the control group (using antiviral treatment regimen excluding IFN-β), and no serious adverse reactions have been observed (Hung et al., 2020).